Loading...

LRMR LARIMAR THERAPEUTICS INC US FDA Inspections 8-K Filing

LRMR

LRMR

LARIMAR THERAPEUTICS INC

(LRMR)

2025 8-K

Summary

Summary

Investor Presentation Update

Positive Study Results

Financial Update

Equity Offerings

Financial Statements

Investor Meetings

Regulatory Compliance

Investor Meetings

Financial Results

Earnings Report

Investor Presentation

Positive Study Data

Investor Presentation

Q3 Earnings Report

Financial Results and Opera...

Presentation Update

Annual Meeting of Stockholders

Other Special Situation

Financial Results and Opera...

Financial Results Announcement

Press Release and Investor ...

Public Offering

Termination of Sales Agreement

Financial Results

Earnings Reports

Appointment of Director

Presentation Update

Financial Results and Opera...

Clinical Trials

Presentation Update

Financial Results and Opera...

Annual Meeting Voting Results

Resignation of Director

Financial Results and Opera...

Presentation Update

External Links:

On September 29, 2025, Larimar Therapeutics, Inc. reported positive data from its study on nomlabofusp for Friedreich’s ataxia, with results from 25 mg and 50 mg doses. The company also hosted a conference call to discuss regulatory updates.

AI Assistant

LARIMAR THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.